Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)

410 participants · First posted Aug 17, 2020

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 participants · First posted Apr 24, 2023

HRD Status Reference Standard Based on WGS

100 participants · First posted Jul 8, 2024

PARPI F-18

C₂₇H₂₂F₂N₄O₃

THG-008

Olaparib-bodipy FL

C₃₄H₃₂BF₃N₆O₃

PARI Pharma GmbH

Germany

PARI RESPIRATORY EQUIPMENT, INC.

United States

ctDNA Analysis Reveals Mechanisms of PARP Inhibitor Resistance in Prostate Cancer

Comparative Analysis of PARP Inhibitors in BRCA-Mutated Ovarian Cancer Shows Similar Efficacy and Toxicity

Blood Test Detects PARPi Resistance in Ovarian Cancer Patients with BRCA1 Mutations